Caixa Capital Risc and Ysios Capital Partners invest 3.5 million Euros in Medlumics
Medlumics devlops medical devices based on optical coherence tomography, a diagnostic technique which is harmless to the patient and is undergoing a major expansion.
BY BIOCAT
“la Caixa”, through Caixa Capital Risc, and Ysios Capital Partners, has closed the first round of financing for the Madrid company, Medlumics, for 3.5 million Euros. Medlumics, founded in 2009, specializes in the development of biophotonic medical devices from a technological platform of integrated optical coherence tomography. Optical coherence tomography (OCT) is a relatively recent imaging technique, which is already used in the fields of ophthalmology, dermatology and cardiology. Its strong point is that it enables high resolution images to be obtained with a capacity to penetrate tissues to a depth of up to 2 millimetres, i.e. it permits the performance of virtual biopsies in a non-invasive way with images of tissues analysed in real time using light.
The technology of Medlumics goes even further, integrating electronic and optical components in robust, easy-to-manufacture devices, which will bring significant savings in costs and maintenance, presently one of the major handicaps, which slows down the growth of this technique. The main applications of Medlumics are currently focused on the fields of cardiology and dentistry, although new medical applications are to be looked into.
The resources of the round of financing will be used for the development of these products and to complete the technical and management team.